The majority of newly diabetic NOD mice treated with the major target determinant insulin B9-23/alum IP or with soluble insulin B9-23 intradermally, in combination with low-dose oral GABA, reverted to hyperglycemia within 5 weeks; however, about 15% remained disease-free for up to 32 weeks (Figure 6). This evidence concerns the gene INS and Hyperglycemia.